ZydusCid is the newer name of Cadila, which is an Indian pharmaceutical company. They recently introduced the WHO-recommended flu vaccine for the year 2025. The vaccine is a quadrivalent seasonal influenza vaccine, meaning it protects against four different strains of the influenza virus: A/Michigan/45/2021, A/California/53/2022, B/Washington/4/2020, and B/Victoria/2/2021.
The introduction of this vaccine comes in a time when Delhi and other parts of North India are experiencing a surge in the spread of respiratory viruses like H3N2 and RSV. The vaccine is manufactured by Zydus’s subsidiary, Zydus Cadila’s Tavir, and is expected to hit the market soon.
According to the Zydus-Cid, this vaccine is the fifth generation of flu vaccine and is more effective than the previous generation. It is expected to provide protection against a broader range of flu strains, reducing the risk of hospitalization due to flu.
The vaccine was developed at Zydus Cadila’s research facility at from Mahapura, Kolkata. According to the company, trials of the vaccine have shown that it provided 100% protection against severe forms of flu and 85% protection against mild forms of the disease.
The WHO recommended flu vaccine for 2025 is the latest addition to the company’s portfolio of vaccines. Zydus Cadila has developed several vaccines, including a vaccine for H1N1, HIV, and TB, and other vaccines for various diseases.